Form 4: Hims & Hers Health CEO Andrew Dudum Executes Stock Options and Sells Shares Under 10b5-1 Plan

Hims & Hers Health CEO Andrew Dudum exercised stock options and sold shares of Class A Common Stock on March 14 and March 17-18, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Andrew Dudum, CEO of Hims & Hers Health, Inc., engaged in multiple transactions involving Class A Common Stock on March 14, 17, and 18, 2025.
• These transactions included the exercise of stock options and the sale of shares, as well as the vesting and settlement of Restricted Stock Units (RSUs).
• On March 14, 2025, Dudum acquired 176,311 shares through the exercise of RSUs.
• Also on March 14, 97,551 shares were withheld by the issuer to cover tax obligations related to the vesting of RSUs.
• On March 17, 2025, Dudum exercised options to purchase 17,001, 50,000, 41,667 and 16,667 shares at a price of $2.43.
• Dudum sold 17,001 shares at $32.9686, 50,000 shares at $35.28, 41,667 shares at $33.4898, 16,667 shares at $32.9562, 2,792 shares at $33.0085, 40,447 shares at $33.5539 and 7,087 shares at $34.1492 on March 17, 2025.
• On March 18, 2025, Dudum sold 57,713 shares at $33.7506 and 21,047 shares at $34.1308.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on August 28, 2024.
• Following these transactions, Dudum directly owns 94,895 shares of Class A Common Stock.
• Dudum also indirectly owns shares through various trusts, including the Dudum Family Community Property Trust (380,262 shares), AD 2022 GRAT 3 (1,194,545 shares), Andrew Dudum 2015 Trust (1,177,133 shares), AD 2021 GRAT (1,286,627 shares), AD 2022 GRAT (534,491 shares), AD 2022 GRAT 2 (829,185 shares), AD 2023 GRAT (1,584,506 shares), and Dudum Family Heritage Trust (2,874,769 shares).

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are part of a pre-planned strategy, but insider selling can sometimes create uncertainty.

Positives

• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, which is generally viewed as a transparent and orderly way for insiders to sell shares.

Negatives

• The CEO selling shares, even under a 10b5-1 plan, could be perceived negatively by some investors, although it's a common practice for executives to diversify their holdings.

Risks

• While the sales are under a 10b5-1 plan, continued selling pressure from insider transactions could potentially impact the stock price.

Future Outlook

The document does not contain specific forward-looking statements, but the ongoing execution of the 10b5-1 trading plan suggests continued stock sales by the CEO.

Industry Context

Insider transactions are common in publicly traded companies, and the use of 10b5-1 plans is a standard practice to avoid accusations of trading on non-public information. Investors often monitor these transactions for insights into management's perspective on the company's value.

Comparison to Industry Standards

• Comparing Dudum's transactions to other CEOs in the telehealth or consumer health space, the scale of these transactions appears within a normal range for executives managing their personal portfolios.
• Similar to executives at companies like Teladoc or GoodRx, Dudum's use of a 10b5-1 plan provides a structured approach to selling shares.
• The vesting schedules of the RSUs are also typical, aligning with standard equity compensation practices in the tech and healthcare industries.

Stakeholder Impact

• Shareholders may react to the news of insider selling, although the existence of a 10b5-1 plan mitigates potential concerns.
• Employees holding company stock or options may also be sensitive to insider trading activity.

Key Dates